Goldman Says FDA Response to Energy Drink Safety Review 'Encouraging' for Monster
Commenting on the action in Monster Beverage this afternoon, Goldman Sachs analyst Judy Hong called the FDA's response to the energy drink safety issue "generally benign." Hong believes this should be encouraging for Monster. The analyst believes the most likely outcome related to Durbin's energy drink review will be strong labeling, something which is unlikely to have a material impact on Monster.
Latest Ratings for MNST
|Mar 2016||Bank of America||Initiates Coverage on||Neutral|
|Mar 2016||Goldman Sachs||Upgrades||Buy||Conviction Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.